Physician
DR Douglas Mehaffie MD LLC
DR Douglas Mehaffie MD LLC was paid $20.31M by Medicaid between Jan 2018 and Dec 2024, across 78 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 25% of everything it billed.
33Billing provider infoDR DOUGLAS MEHAFFIE MD LLC
GRETNA, LA 70056
GRETNA, LA 70056
33aNPI1669409199assigned 06/28/2006
33bProvider typeFamily Medicine Physician
28Total paid$20.31M
24GClaims456,995
24DCodes billed78
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Louisiana
Rank by total paid#2 of 417
Median peer was paid$63K
This provider vs. median323×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,701 | $1.31M | |
| 2019 | 43,985 | $1.55M | |
| 2020 | 43,316 | $1.88M | |
| 2021 | 69,887 | $3.44M | |
| 2022 | 70,899 | $3.45M | |
| 2023 | 104,119 | $4.96M | |
| 2024incomplete | 90,088 | $3.72M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 25% | 95,223 | 83,407 | $5.05M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 16% | 39,696 | 36,513 | $3.25M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 9.8% | 33,541 | 28,764 | $2.00M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 9.8% | 29,985 | 26,520 | $1.99M |
| 87634 | 7.3% | 30,266 | 26,459 | $1.48M | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 5.1% | 7,726 | 4,964 | $1.04M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.1% | 17,563 | 15,729 | $620K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.6% | 7,369 | 6,464 | $538K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.3% | 9,223 | 7,667 | $458K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.1% | 7,975 | 7,431 | $430K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.1% | 14,713 | 12,658 | $423K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.9% | 5,230 | 4,543 | $382K |
66 more codes
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.5% | 8,778 | $296K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.3% | 23,205 | $255K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.2% | 22,211 | $234K |
| 87481 | 1.1% | 2,004 | $224K | |
| 99205 | Prolong outpt/office vis | <1% | 1,667 | $181K |
| 87653 | <1% | 7,274 | $179K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,749 | $141K |
| 87529 | <1% | 2,346 | $128K | |
| 87486 | <1% | 5,044 | $120K | |
| 87581 | <1% | 4,925 | $119K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,808 | $110K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,798 | $110K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,780 | $93K |
| 81025 | <1% | 13,190 | $68K | |
| 87640 | <1% | 2,107 | $59K | |
| 87511 | <1% | 1,972 | $55K | |
| 82075 | <1% | 3,044 | $32K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 729 | $26K |
| 0012A | <1% | 886 | $23K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,395 | $20K |
| 0011A | <1% | 904 | $20K | |
| 81003 | <1% | 10,188 | $18K | |
| 80305 | <1% | 1,992 | $18K | |
| 80348 | <1% | 1,178 | $16K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 714 | $13K |
| 0001A | <1% | 376 | $13K | |
| 0002A | <1% | 324 | $11K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 239 | $8K |
| 93000 | <1% | 656 | $8K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 607 | $5K |
| 94664 | <1% | 496 | $4K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 194 | $3K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 87 | $3K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 17 | $3K |
| 87807 | <1% | 257 | $3K | |
| 0064A | <1% | 79 | $3K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 188 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,264 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,045 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 142 | $2K |
| 80076 | <1% | 198 | $1K | |
| 82962 | <1% | 554 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 631 | $1K |
| 90686 | <1% | 61 | $856.39 | |
| 73630 | <1% | 42 | $764.40 | |
| 0071A | <1% | 18 | $747.44 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 546 | $545.31 |
| 90715 | <1% | 15 | $506.24 | |
| 91301 | <1% | 1,524 | $482.04 | |
| 99173 | <1% | 390 | $425.24 | |
| 86769 | <1% | 29 | $421.30 | |
| 74018 | <1% | 13 | $247.65 | |
| 99051 | <1% | 56 | $240.84 | |
| 73610 | <1% | 12 | $235.20 | |
| 73140 | <1% | 13 | $188.32 | |
| 80053 | Comprehensive metabolic panel | <1% | 14 | $138.84 |
| 69209 | <1% | 16 | $118.65 | |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 385 | $47.61 |
| 99000 | <1% | 2,109 | $33.75 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 141 | $7.88 |
| A9150 | Non-prescription drugs | <1% | 2,408 | $6.56 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 489 | $1.96 |
| 91300 | <1% | 727 | $1.21 | |
| 91306 | 0% | 68 | $0.00 | |
| 91307 | 0% | 42 | $0.00 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 125 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMEHAFFIE, DOUGLAS (OWNER)